Microbiological characteristics of clinical isolates of Cryptococcus neoformans in Taiwan: serotypes, mating types, molecular types, virulence factors, and antifungal susceptibility

Clinical Microbiology and Infection

Volumn 16, Issue 6, 2010, Pages 696-703

  Liaw, S J ^b   Wu, H C ^a   Hsueh, P R ^c  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b Departments of Medicine   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Antifungal susceptibility; Cryptococcus neoformans; Mating types; Molecular types; Serotypes; Virulence

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; LACTATE DEHYDROGENASE; MELANIN; PHOSPHOLIPASE; UREASE; VORICONAZOLE;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CELL ADHESION; CELL DAMAGE; CONTROLLED STUDY; CRYPTOCOCCUS NEOFORMANS; ENZYME ACTIVITY; EPITHELIUM CELL; FEMALE; FUNGAL VIRULENCE; FUNGICIDAL ACTIVITY; HUMAN; HUMAN CELL; MALE; MATING TYPE; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR TYPING; NONHUMAN; PIGEON; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEROTYPE; TAIWAN;

COLUMBA; FILOBASIDIELLA NEOFORMANS;

EID: 77953945423     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2009.02930.x     Document Type: Article

References (42)

1. Mitchell TG, Perfect JR. Cryptococcosis in the era of AIDS-100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev 1995, 8:515-548.
2. Kwon-Chung KJ, Varma A. Do major species concepts support one, two or more species within Cryptococcus neoformans? FEMS Yeast Res 2006, 6:574-587.
3. Franzot SP, Salkin IF, Casadevall A. Cryptococcus neoformans var. grubii: separate varietal status for Cryptococcus neoformans serotype A isolates. J Clin Microbiol 1999, 37:838-840.
4. Kwon-Chung KJ. A new genus, Filobasidiella, the perfect state of Cryptococcus neoformans. Mycologia 1975, 67:1197-1200.
5. Casali AK, Goulart L, Rosa e Silva LK. Molecular typing of clinical and environmental Cryptococcus neoformans isolates in the Brazilian state Rio Grande do Sul. FEMS Yeast Res 2003, 3:405-415.
6. Kwon-Chung KJ, Wickes BL, Booth JL, Vishniac HS, Bennett JE. Urease inhibition by EDTA in the two varieties of Cryptococcus neoformans. Infect Immun 1987, 55:1751-1754.
7. Kwon-Chung KJ, Varma A, Edman JC, Bennett JE. Selection of ura5 and ura3 mutants from the two varieties of Cryptococcus neoformans on 5-fluoroorotic acid medium. J Med Vet Mycol 1992, 30:61-69.
8. Chen J, Varma A, Diaz MR, Litvintseva AP, Wollenberg KK, Kwon-Chung KJ. Cryptococcus neoformans strains and infection in apparently immunocompetent patients, China. Emerg Infect Dis 2008, 14:755-762.
9. Kwon-Chung KJ. Morphogenesis of Filobasidiella neoformans, the sexual state of Cryptococcus neoformans. Mycologia 1976, 68:821-833.
10. Wickes BL, Mayorga ME, Edman U, Edman JC. Dimorphism and haploid fruiting in Cryptococcus neoformans: association with the alpha-mating type. Proc Natl Acad Sci USA 1996, 93:7327-7331.
11. Nielsen K, Cox GM, Litvintseva AP. Cryptococcus neoformanslalphar strains preferentially disseminate to the central nervous system during coinfection. Infect Immun 2005, 73:4922-4933.
12. Meyer W, Castaneda A, Jackson S, Huynh M, Castaneda E. Molecular typing of IberoAmerican Cryptococcus neoformans isolates. Emerg Infect Dis 2003, 9:189-195.
13. Meyer W, Marszewska K, Amirmostofian M. Molecular typing of global isolates of Cryptococcus neoformans var. neoformans by polymerase chain reaction fingerprinting and randomly amplified polymorphic DNA-a pilot study to standardize techniques on which to base a detailed epidemiological survey. Electrophoresis 1999, 20:1790-1799.
14. Saag MS, Graybill RJ, Larsen RA. Practice Guidelines for the Management of Cryptococcal Disease. Infectious Diseases Society of America. Clin Infect Dis 2000, 30:710-718.
15. Hsueh PR, Lau YJ, Chuang YC. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003. Antimicrob Agents Chemother 2005, 49:512-517.
16. Chen YC, Chang SC, Shih CC. Clinical features and in vitro susceptibilities of two varieties of Cryptococcus neoformans in Taiwan. Diagn Microbiol Infect Dis 2000, 36:175-183.
17. Buchanan KL, Murphy JW. What makes Cryptococcus neoformans a pathogen? Emerg Infect Dis 1998, 4:71-83.
18. Cox GM, Mukherjee J, Cole GT, Casadevall A, Perfect JR. Urease as a virulence factor in experimental cryptococcosis. Infect Immun 2000, 68:443-448.
19. Cox GM, McDade HC, Chen SC. Extracellular phospholipase activity is a virulence factor for Cryptococcus neoformans. Mol Microbiol 2001, 39:166-175.
20. Clancy CJ, Nguyen MH, Alandoerffer R. Cryptococcus neoformans var. grubii isolates recovered from persons with AIDS demonstrate a wide range of virulence during murine meningoencephalitis that correlates with the expression of certain virulence factors. Microbiology 2006, 152:2247-2255.
21. Blackstock R, Buchanan KL, Cherniak R. Pathogenesis of Cryptococcus neoformans is associated with quantitative differences in multiple virulence factors. Mycopathologia 1999, 147:1-11.
22. Siafakas AR, Sorrell TC, Wright LC. Cell wall-linked cryptococcal phospholipase B1 is a source of secreted enzyme and a determinant of cell wall integrity. J Biol Chem 2007, 282:37508-37514.
23. Vidotto V, Leone R, Sinicco A, Ito-kuwa S, Criseo G. Comparison of phospholipase production in Cryptococcus neoformans isolates from AIDS patients and bird droppings. Mycopathologia 1998, 142:71-76.
24. Vidotto V, Sinicco A, Di Fraia D, Cardaropoli S, Aoki S, Ito-Kuwa S. Phospholipase activity in Cryptococcus neoformans. Mycopathologia 1996, 136:119-123.
25. Chen SC, Muller M, Zhou JZ, Wright LC, Sorrell TC. Phospholipase activity in Cryptococcus neoformans: a new virulence factor? J Infect Dis 1997, 175:414-420.
26. Silva EG, Baroni Fde A, Viani FC. Virulence profile of strains of Cryptococcus neoformans var. grubii evaluated by experimental infection in BALB/c mice and correlation with exoenzyme activity. J Med Microbiol 2006, 55:139-142.
27. Hazen KC, Howell SA. Candida, Cryptococcus, and other yeasts of medical importance. Manual of clinical microbiology 2003, 2:1711. Murray PR, Baron EJJorgensen JHPfaller MAYolken RH. eds, 8th edn, Vol, Washington, DC, American Society for Microbiology
28. Lindsley MD, Hurst SF, Iqbal NJ, Morrison CJ. Rapid identification of dimorphic and yeast-like fungal pathogens using specific DNA probes. J Clin Microbiol 2001, 39:3505-3511.
29. Enache-Angoulvant A, Chandenier J, Symoens F. Molecular identification of Cryptococcus neoformans serotypes. J Clin Microbiol 2007, 45:1261-1265.
30. Ito-Kuwa S, Nakamura K, Aoki S, Vidotto V. Serotype identification of Cryptococcus neoformans by multiplex PCR. Mycoses 2007, 50:277-281.
31. Reference method for broth microdilution antifungal susceptibility testing of yeasts. Approved Standard M27-A2 2002, Wayne, PA, National Committee for Clinical Laboratory Standards
32. Eisenman HC, Mues M, Weber SE. Cryptococcus neoformans laccase catalyses melanin synthesis from both D- and L-DOPA. Microbiology 2007, 153:3954-3962.
33. Barbosa FM, Fonseca FL, Holandino C, Alviano CS, Nimrichter L, Rodrigues ML. Glucuronoxylomannan-mediated interaction of Cryptococcus neoformans with human alveolar cells results in fungal internalization and host cell damage. Microbes Infect 2006, 8:493-502.
34. Guillot L, Carroll SF, Badawy M, Qureshi ST. Cryptococcus neoformans induces IL-8 secretion and CXCL1 expression by human bronchial epithelial cells. Respir Res 2008, 9.
35. van Duin D, Casadevall A, Nosanchuk JD. Melanization of Cryptococcus neoformans and Histoplasma capsulatum reduces their susceptibilities to amphotericin B and caspofungin. Antimicrob Agents Chemother 2002, 46:3394-3400.
36. Chang WN, Huang CR, Lei CB. Serotypes of clinical cerebrospinal fluid Cryptococcus neoformans isolates from southern Taiwan and their in vitro susceptibilities to amphotericin B, fluconazole, and voriconazole. Jpn J Infect Dis 2004, 57:113-115.
37. Viviani MA, Cogliati M, Esposto MC. Molecular analysis of 311 Cryptococcus neoformans isolates from a 30-month ECMM survey of cryptococcosis in Europe. FEMS Yeast Res 2006, 6:614-619.
38. Escandon P, Sanchez A, Martinez M, Meyer W, Castaneda E. Molecular epidemiology of clinical and environmental isolates of the Cryptococcus neoformans species complex reveals a high genetic diversity and the presence of the molecular type VGII mating type a in Colombia. FEMS Yeast Res 2006, 6:625-635.
39. Cogliati M, Esposto MC, Liberi G, Tortorano AM, Viviani MA. Cryptococcus neoformans typing by PCR fingerprinting using (GACA)4 primers based on C. neoformans genome project data. J Clin Microbiol 2007, 45:3427-3430.
40. Doering TL, Nosanchuk JD, Roberts WK, Casadevall A. Melanin as a potential cryptococcal defence against microbicidal proteins. Med Mycol 1999, 37:175-181.
41. Wang Y, Casadevall A. Growth of Cryptococcus neoformans in presence of L-dopa decreases its susceptibility to amphotericin B. Antimicrob Agents Chemother 1994, 38:2648-2650.
42. Ikeda R, Sugita T, Jacobson ES, Shinoda T. Effects of melanin upon susceptibility of Cryptococcus to antifungals. Microbiol Immunol 2003, 47:271-277.